RiNA GmbH Acquires Roche RTS Protein Expression Portfolio

10-Sep-2009 - Germany

Roche and RiNA GmbH of Berlin have agreed to transfer the complete Roche Applied Science RTS protein expression portfolio to RiNA GmbH, effective September 15, 2009. RiNA will contribute its experience in the field of cell-free Expression systems and continue production at the same quality standards defined by Roche. Responsible for sales, support, and distribution of the RTS portfolio worldwide will be 5 PRIME GmbH of Hamburg, adding a global team of support, direct sales, and distributors. Both partners are committed to maintaining unchanged quality and price of RTS products.

“Roche Applied Science is focusing on innovative technologies in genomics, and we believe that a company specializing in proteomics will be able to develop the potential of RTS technology much faster than we can,” states Manfred Baier, Head of Roche Applied Science.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances